Syntellix's acquisition of 73% stake in materials specialist MSE results in strategically important vertical integration ahead of intended international flotation
Geschrieben am 28-08-2018 |
Hannover (ots) - At yesterday's AGM, shareholders of Syntellix AG
approved all the management's proposed resolutions by an overwhelming
majority of 99%.
- Preparations for the intended IPO will be supported by a
multinational Supervisory Board comprising internationally renowned
personalities from the world of finance.
With its patented MAGNEZIX® magnesium technology, Syntellix AG is
currently in the process of redefining the global market for
orthopaedic implants and in doing so has achieved significant
progress during the current year. At its annual general meeting
yesterday, the company announced that as part of a capital increase
it will acquire a 73% stake in material supplier Materials Science
and Engineering Werkstoffzentrum Clausthal GmbH (MSE) and thereby
further enhance its successful strategic partnership with the MSE
group of Prof. Neubert and his family, which was responsible for
making the globally unique innovation MAGNEZIX® possible in the first
place. This vertical integration is regarded as an important step in
the run-up to Syntellix's proposed international flotation and was
received with enthusiasm by the company's domestic and foreign
investors.
At yesterday's AGM, Syntellix's shareholders also approved all the
actions proposed by the management by an overwhelming majority of
over 99% of the voting stock. Even if the votes of the main
shareholder, Prof. Claassen, had not been taken into account, there
would still have been 99% approval for all the proposed resolutions.
The company's investors, who have already expressed their support to
a very notable extent by injecting capital as part of several
successful capital increases during the current year, thus were in
complete agreement on all upcoming formal, structural and strategic
steps.
Syntellix's CEO, founder and main shareholder, Prof. Dr. Utz
Claassen explains: "The acquisition of the majority stake in MSE in
Clausthal with its unique competence in materials science and
production engineering represents an extremely significant and a
highly satisfactory step for Syntellix in the run-up to the intended
flotation. As was again demonstrated impressively at yesterday's AGM,
it is also pleasing that there is fantastic agreement between
Syntellix's investors concerning the correctness of the approach
being adopted to tap the enormous potential as well as regarding the
respective measures that have been taken and the milestones that have
been reached this year. Quite a few major corporations could have
been excused for being envious of us when two globally renowned
personalities from the world of finance, Jürgen Fitschen and Steven
F. Mayer, were elected to the Supervisory Board. Highly competent
nationals from the Republic of Singapore, the People's Republic of
China and the United States of America will join the members from
Germany in future."
About Syntellix:
Syntellix AG is an internationally operating, dynamically growing
medical technology company, headquartered in Hannover (Germany). The
company specializes in research, development, marketing and
distribution of highly innovative transformable metallic implants.
The products, which are made of the patented material MAGNEZIX®, are
unique and, in a recent publication, have been found to be clinically
superior compared with common titanium implants. They degrade in the
body and are transformed into endogeneous bone tissue while providing
a favourable combination of stability, elasticity and
bioabsorbability.
Syntellix AG is the global market and technology leader in the
area of bioabsorbable metallic orthopaedic implants and has already
been honored with many major awards and prizes, including the
Innovation Prize of the German Economy 2012/13, the Future Prize of
the Health Industry 2016, the German Medical Award 2017, the STEP
Award 2017, and the "Innovator of the Year 2017" in Germany;
internationally the implants were a winner in the Product of the Year
category of the Sustainability Award 2018 program.
Pressekontakt:
Caroline Meyer-Maltseva
PR
T +49 511 270413-55
presse@syntellix.com
www.syntellix.com
Syntellix AG
Aegidientorplatz 2a
30159 Hanover
Germany
Original-Content von: Syntellix AG, übermittelt durch news aktuell
Kontaktinformationen:
Leider liegen uns zu diesem Artikel keine separaten Kontaktinformationen gespeichert vor.
Am Ende der Pressemitteilung finden Sie meist die Kontaktdaten des Verfassers.
Neu! Bewerten Sie unsere Artikel in der rechten Navigationsleiste und finden
Sie außerdem den meist aufgerufenen Artikel in dieser Rubrik.
Sie suche nach weiteren Pressenachrichten?
Mehr zu diesem Thema finden Sie auf folgender Übersichtsseite. Desweiteren finden Sie dort auch Nachrichten aus anderen Genres.
http://www.bankkaufmann.com/topics.html
Weitere Informationen erhalten Sie per E-Mail unter der Adresse: info@bankkaufmann.com.
@-symbol Internet Media UG (haftungsbeschränkt)
Schulstr. 18
D-91245 Simmelsdorf
E-Mail: media(at)at-symbol.de
651511
weitere Artikel:
- T-Systems-CEO Al-Saleh: "Wir müssen jedes Jahr zehn Prozent effizienter werden, das fordern die Kunden" München (ots) - Umbau der Geschäftsstruktur / Reduzierung der
Niederlassungen auf 25 / Wachstum von zwei Prozent jährlich
angestrebt / Fokus auf zukunftsfähige und profitable Geschäftsfelder
München, 28. August 2018 - T-Systems-CEO Adel Al-Saleh will auf
die Forderungen der Kunden nach mehr Effizienz und schlankeren
Strukturen reagieren. Im Interview mit der Online-Ausgabe der
IT-Fachzeitschrift "Computerwoche" konkretisierte er die Pläne für
einen umfassenden Umbau der Telekom-IT-Tochter. Neben der Justierung
der Geschäftsfelder mehr...
- Starker Auftritt für den Heurigen Ott - BILD Eine symbolstarke Architektur macht den Besuch zur Zeitreise.
Der Umbau des Heurigenlokals in Hagenbrunn durch Spitzbart +
partners ist der erste Schritt zum neuen Markenauftritt.
Oberösterreich/Kirchham/Laakirchen (ots) - Zeitgeist trifft auf
Heurigenkultur; Design auf Bodenständigkeit. Die Harmonisierung
dieser Gegensätze gelang Spitzbart + partners, Spezialist für
Konzeption, Architektur und Einrichtung, beim Umbau des Heurigen Ott
in Hagenbrunn. Die Wiedereröffnung fand im Frühsommer 2018 statt.
An der Spitze des Vorzeigebetriebs mehr...
- Konsum von elektronischen Zigaretten kann Schäden durch Tabakrauchen bei COPD-Patienten selbst langfristig umkehren New York (ots/PRNewswire) - Eine neue, kürzlich im International
Journal of Chronic Obstructive Pulmonary Disease veröffentlichte
Studie unter der Leitung von Riccardo Polosa, MD, PhD (Abteilung für
Klinische und Experimentelle Medizin an der Universität Catania,
Italien) lässt darauf schließen, dass der Konsum von elektronischen
Zigaretten (E-Zigaretten) einen Teil der durch Tabakrauchen
verursachten Schäden bei Patienten mit chronisch obstruktiver
Lungenerkrankung (Chronic Obstructive Pulmonary Disease, COPD)
rückgängig machen mehr...
- CAPE 2018 findet im September in Chongqing, China, statt Die Veranstaltung präsentiert führende Automobiltechnologien und
zieht die Aufmerksamkeit weltweiter Branchenexperten auf sich
Shanghai (ots/PRNewswire) - Chongqing International Auto Parts and
Service Exhibition 2018 (CAPE 2018) wird vom 19.-21. September 2018
im Chongqing International Expo Center stattfinden. Die
Veranstaltung wird gemeinsam von der Shanghaier Zweigstelle des China
Council for The Promotion of International Trade (CCPIT), dem CCPIT
Automotive Unterausschuss, der Shanghai International Exhibition Co.,
Ltd. und mehr...
- Duzallo®, a fixed-dose combination therapy for gout, approved in Europe Aachen (ots) - Today, Grünenthal announced that the European
Commission has followed the positive opinion of the Committee for
Medicinal Products for Human Use (CHMP) and granted Duzallo®
marketing authorization for the EU/EEA. Duzallo® is a fixed-dose
combination (FDC) therapy that combines allopurinol and lesinurad. It
is indicated for the treatment of hyperuricaemia in adult gout
patients who have not been able to reach target levels of uric acid
serum with a dose of allopurinol alone. Lesinurad is the first
innovative uricosuric mehr...
|
|
|
Mehr zu dem Thema Aktuelle Wirtschaftsnews
Der meistgelesene Artikel zu dem Thema:
DBV löst Berechtigungsscheine von knapp 344 Mio. EUR ein
durchschnittliche Punktzahl: 0 Stimmen: 0
|